《BioRxiv,5月23日,Systemic Effects of Missense Mutations on SARS-CoV-2 Spike Glycoprotein Stability and Receptor Binding Affinity》

  • 来源专题:COVID-19科研动态监测
  • 编译者: zhangmin
  • 发布时间:2020-05-24
  • Systemic Effects of Missense Mutations on SARS-CoV-2 Spike Glycoprotein Stability and Receptor Binding Affinity

    View ORCID ProfileShaolei Teng, Adebiyi Sobitan, Raina Rhoades, Dongxiao Liu, Qiyi Tang

    doi: https://doi.org/10.1101/2020.05.21.109835

    Abstract

    The spike (S) glycoprotein of SARS-CoV-2 is responsible for the binding to the permissive cells. The receptor-binding domain (RBD) of SARS-CoV-2 S protein directly interacts with the human angiotensin-converting enzyme 2 (ACE2) on the host cell membrane. In this study, we used computational saturation mutagenesis approaches, including structure-based energy calculations and sequence-based pathogenicity predictions, to quantify the systemic effects of missense mutations on SARS-CoV-2 S protein structure and function. A total of 18,354 mutations in S protein were analyzed and we discovered that most of these mutations could destabilize the entire S protein and its RBD. Specifically, residues G431 and S514 in SARS-CoV-2 RBD are important for S protein stability. We analyzed 384 experimentally verified S missense variations and revealed that the dominant pandemic form, D614G, can stabilize the entire S protein. Moreover, many mutations in N-linked glycosylation sites can increase the stability of the S protein.

    *注,本文为预印本论文手稿,是未经同行评审的初步报告,其观点仅供科研同行交流,并不是结论性内容,请使用者谨慎使用.

  • 原文来源:https://www.biorxiv.org/content/early/2020/05/23/2020.05.21.109835
相关报告
  • 《BioRxiv,3月17日,RBD mutations from circulating SARS-CoV-2 strains enhance the structure stability and infectivity of the spike protein》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-03-18
    • RBD mutations from circulating SARS-CoV-2 strains enhance the structure stability and infectivity of the spike protein Junxian Ou, Zhonghua Zhou, Jing Zhang, Wendong Lan, Shan Zhao, Jianguo Wu, Donald Seto, Gong Zhang, Qiwei Zhang doi: https://doi.org/10.1101/2020.03.15.991844 Abstract A novel zoonotic coronavirus SARS-CoV-2 is associated with the current global pandemic of Coronavirus Disease 2019 (COVID-19). Bats and pangolins are suspected as the reservoir and the intermediate host. The receptor binding domain (RBD) of the SARS-CoV-2 S protein plays the key role in the tight binding to human ACE2 for viral entry. In this study, we analyzed the worldwide RBD mutations and found 10 mutants revealed high positive selection pressure during the spread. The equilibrium dissociation constant (KD) of three RBD mutants were two orders of magnitude lower than the prototype Wuhan-Hu-1 strain due to the stabilization of the beta-sheet scaffold of the RBD. *注,本文为预印本论文手稿,是未经同行评审的初步报告,其观点仅供科研同行交流,并不是结论性内容,请使用者谨慎使用.
  • 《BioRxiv,3月17日,A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-03-18
    • A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein M. Gordon Joyce, Rajeshwer S Sankhala, Wei-Hung Chen, Misook Choe, Hongjun Bai, Agnes Hajduczki, Lianying Yan, Spencer L Sterling, Caroline Peterson, Ethan C Green, Clayton Smith, Natalia de Val, Mihret Amare, Paul Scott, Eric D Laing, Christopher C Broder, Morgane Rolland, Nelson L Michael, Kayvon Modjarrad doi: https://doi.org/10.1101/2020.03.15.992883 Abstract SARS-CoV-2 is a zoonotic virus that has caused a pandemic of severe respiratory disease—COVID-19—within several months of its initial identification. Comparable to the first SARS-CoV, this coronaviruses surface Spike (S) glycoprotein mediates cell entry via the human ACE-2 receptor, and, thus, is the principal target for the development of vaccines and immunotherapeutics. Molecular information on the SARS-CoV-2 S glycoprotein remains limited. Here we report the crystal structure of the SARS-CoV-2 S receptor-binding-domain (RBD) at a the highest resolution to date, of 1.95 Å. We identified a set of SARS-reactive monoclonal antibodies with cross-reactivity to SARS-CoV-2 RBD and other betacoronavirus S glycoproteins. *注,本文为预印本论文手稿,是未经同行评审的初步报告,其观点仅供科研同行交流,并不是结论性内容,请使用者谨慎使用.